Cantel Medical Corp

Cantel Medical — Investor Presentation (November 2012)

22 slides from Cantel Medical's investor presentation, Nov 13, 2012

  1. Slide 1: Infection Prevention & Control Matters

    Slide 1: Infection Prevention & Control Matters

    Cantel Medical Corp. (NYSE: CMN) Infection Prevention & Control Matters™ Nov. 2012 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements. All forward-looking statements involve risks and uncertainties, including, without limitation, the risks detailed in the Company’s filin

  2. Slide 2: Cantel Medical Corp. $386M NYSE Leader in Infection Prevention & Control

    Slide 2: Cantel Medical Corp. $386M NYSE Leader in Infection Prevention & Control

    2 Cantel Medical Corp. $386M NYSE Leader in Infection Prevention & Control Pure-play in a ~$45B Global Infection Prevention & Control Market (“IP&C”) Large, highly fragmented = growth opportunities 18 acquisitions since 2001 have re-shaped the company Have never been better positioned for future gro

  3. Slide 3: Three Synergistic Platforms

    Slide 3: Three Synergistic Platforms

    3 Cantel Medical Corp. Three Synergistic Platforms IInfection nfection PPrevention revention && CControl Focusontrol Focus Healthcare & Life Sciences Orientation IP&C Device Management Endoscopy & Renal Dialysis Medivators/Byrne; Minntech Purification & Filtration Water Treatment & Therapeutic Filte

  4. Slide 4: Snapshot: By Product, Customer, Channel

    Slide 4: Snapshot: By Product, Customer, Channel

    4 Cantel Medical Corp. Snapshot: By Product, Customer, Channel Infection Prevention & Control Focus Healthcare & Life Sciences Orientation Dialysis Equipment, Sterilants, Consumables, Service Endoscopy Equipment, Disinfectants, Consumables, Service Water Purification Equipment, Field Service, Consum

  5. Slide 5: $45 Billion Global Market

    Slide 5: $45 Billion Global Market

    5 Cantel Medical Corp. $45 Billion Global Infection Prevention & Control Market Healthcare Associated Infections (HAI’s) are the most common complication of hospital care2 Implementing existing prevention practices yields ~70% reduction in HAIs. Financial benefit ~$25B - $32B in medical cost savings

  6. Slide 6: Healthcare Reform Creates Greater Emphasis in IP&C

    Slide 6: Healthcare Reform Creates Greater Emphasis in IP&C

    6 Cantel Medical Corp. Healthcare Reform Creates Greater Emphasis in IP&C Financial Penalties to Hospitals1 Preventable Readmissions – Estimated $30 billion cost to the system Beginning 2012, Medicare will stop paying hospitals for preventable readmissions tied to heart failure or pneumonia Beginnin

  7. Slide 7: Well-Balanced Portfolio with Emphasis on Endoscopy

    Slide 7: Well-Balanced Portfolio with Emphasis on Endoscopy

    7 Cantel Medical Corp. Well-Balanced Portfolio with Emphasis on Endoscopy Fiscal Year Ended July 31, 2012 “All Other” includes Therapeutic Filtration Products. Specialty Packaging Products, and Chemistries. 1 Before allocation of corporate expenses of ~$11.6M. 2 Earnings Before Interest, Taxes, Depr

  8. Slide 8: Significant Upside Growth Opportunities

    Slide 8: Significant Upside Growth Opportunities

    8 Cantel Medical Corp. Significant Upside Growth Opportunities Acquisitions: 4 recent acquisitions in all three core segments SPSmedical Supply Corp. combined with ConFirm Monitoring creates a leading sterility assurance monitoring platform to drive further growth in acute care, dental and physician

  9. Slide 9: Significant Upside Growth Opportunities

    Slide 9: Significant Upside Growth Opportunities

    9 Cantel Medical Corp. Significant Upside Growth Opportunities Substantial Sales & Marketing investments in core FY’09-FY’12 Substantial increase in R&D spending in FY’11-FY’12 High-Margin Liquid Chemical Germicides (LCG) New chemistry development capabilities began in FY’11, to yield multiple New P

  10. Slide 10: Byrne Acquisition – Aug 1, 2011

    Slide 10: Byrne Acquisition – Aug 1, 2011

    10 Byrne Acquisition – Aug 1, 2011 Endoscopy: Facilitate Accelerated Global Growth Medivators (f/k/a Minntech) subsidiary acquired the assets of Byrne Medical, Inc. for $89.4M in cash and $10.0M in stock, plus $10.0M potential earnout Pre-acquisition revenues of ~$38.6M and EBIT of $10.9M1 Complemen

  11. Slide 11: Endoscopy Segment: Complementary Businesses

    Slide 11: Endoscopy Segment: Complementary Businesses

    11 Medivators Plus Byrne Medical Endoscopy Segment: Complementary Businesses Intercept Wipes Veriscan Scope Buddy Intercept CER/DSD/ Advantage Rapicide Rapicide PA IN THE PROCEDURE ROOM Byrne Medical Products Treatment Room Physicians & Nurses Medivators Endoscope Reprocessing Products Principally i

  12. Slide 12: SPSmedical and ConFirm Acquisitions

    Slide 12: SPSmedical and ConFirm Acquisitions

    12 SPSmedical and ConFirm Acquisitions Creates Leading Sterility Assurance Monitoring Platform Crosstex subsidiary acquired SPSmedical Supply Corp. (Nov. 2, 2012) for $32.5M in cash, plus $3.5M for facility. Pre-acquisition revenue of $17.5M Follow on to the prior acquisition of ConFirm Monitoring S

  13. Slide 13: Gambro Acquisition in FY'11

    Slide 13: Gambro Acquisition in FY'11

    13 Gambro Acquisition in FY’11 Water Treatment Mar Cor Purification subsidiary acquired Gambro’s U.S. water treatment business (Oct 6, 2010) for $23.7M in cash. Pre-acquisition revenues of ~$14.0M. Strategic value akin to success of Mar Cor’s acquisition of GE’s Dialysis Water Business in March 2007

  14. Slide 14: Formula: Acquire, Improve Businesses, Repeat

    Slide 14: Formula: Acquire, Improve Businesses, Repeat

    FY'03FY'04FY'05FY'06FY'07FY'08FY'09FY'10FY'11*FY'12Net Sales$94.0$123.0$137.2$192.2$219.0$249.4$260.1$274.0$321.7$386.5EBITDAS$11.3$14.0$19.2$26.5$28.6$31.8$42.1$47.5$47.1$72.0Net Debt/(Cash)$3.7$7.1($17.6)$8.1$41.1$40.0$19.9($1.6)$103.6$59.8EBITDAS Margin12.0%11.4%14.0%13.8%13.0%12.8%16.2%17.3%14.7

  15. Slide 15: Fragmented Nature of the Market

    Slide 15: Fragmented Nature of the Market

    15 Cantel Medical Corp. Fragmented Nature of Infection Prevention & Control 12345Disinfectants & CleanersDisposablesMasks / HeadwearAir & Water QualityProtective ApparelBrushesDisposable kits / traysFace shieldsAir filtration systemsAprons / bibs / arm protectorsDispensersDisposable medical products

  16. Slide 16: Historical P&L Reveals Success of Acquisition Program

    Slide 16: Historical P&L Reveals Success of Acquisition Program

    16 Cantel Medical Corp. Historical P&L Reveals Success of Acquisition Program 1 Earnings before Interest, Taxes, Depreciation, Amortization, and Stock Compensation Expense. 2 Equivalent to “Income from Continuing Operations”. 3 Compound Annual Growth Rate. 4 Retroactively applies the 3:2 stock split

  17. Slide 17: Capacity for Continued Investment

    Slide 17: Capacity for Continued Investment

    17 Cantel Medical Corp. Capacity for Continued Investment 2006200720082009201020112012$238.2 $263.7 $279.2 $277.9 $280.7 $321.4 $434.8 2.1:12.1:12.2:12.3:12.3:12.6:12.4:1$140.8 $155.1 $168.7 $187.1 $209.4 $234.3 $275.9 0.270.370.350.230.100.5210.331.4x2.0x1.8x1.0x0.4x2.6x11.3x24.424.224.724.925.526.

  18. Slide 18: Experienced Executive Team – Now organizing for growth

    Slide 18: Experienced Executive Team – Now organizing for growth

    Cantel Medical Corp. Experienced Executive Team – Now organizing for growth Andrew A. Krakauer President & CEO Jorgen B. Hansen Exec. Vice President & Chief Operating Officer Eric W. Nodiff Sr. Vice President General Counsel Craig A. Sheldon Sr. Vice President Chief Financial Officer & Treasurer Set

  19. Slide 19: Strategic Objectives Remain Focused

    Slide 19: Strategic Objectives Remain Focused

    19 Cantel Medical Corp. Strategic Objectives Remain Focused within Infection Prevention & Control Near-term build a profitable $500 Million Specialty Business…setting the strategy for $1 Billion Achieve accelerated growth and profits from the three recent acquisitions Invest in higher technology, hi

  20. Slide 20: Strategic Evolution

    Slide 20: Strategic Evolution

    20 Cantel Medical Corp. Strategic Evolution FY’04 – FY’08: Acquire and Define Infection Prevention & Control (IPC) Portfolio FY’09 – FY’10: Substantial Operational and P&L Improvement, while Investing in Sales & Marketing FY’11: Leverage Sales & Marketing and Drive R&D Investments. Close 1-2 Key Acq

  21. Slide 21: Summary

    Slide 21: Summary

    21 Cantel Medical Corp. Summary Growing ~$45B Global Market in Infection Prevention & Control Pure-play focus Fragmented nature creates opportunities for further growth and expansion $386M NYSE Specialty Infection Prevention & Control Leader Strong, recession-buffered core business with high future

  22. Slide 22: Infection Prevention & Control Matters

    Slide 22: Infection Prevention & Control Matters

    Cantel Medical Corp. (NYSE: CMN) Infection Prevention & Control Matters™

Source: SEC EDGAR · 8-K filed Nov 13, 2012

More decks from Cantel Medical Corp